gms | German Medical Science

77. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

24.05. - 28.05.2006, Mannheim

Magnetic Drug Targeting in Head and Neck Carcinomas

Meeting Abstract

Suche in Medline nach

  • corresponding author presenting/speaker Christoph Alexiou - Univ.-HNO Erlangen, Erlangen, Germany
  • Roland Jurgons - Univ.-HNO Erlangen, Erlangen, Germany
  • Christian Seliger - Univ.-HNO Erlangen, Erlangen, Germany
  • Heinrich Iro - Univ.-HNO Erlangen, Erlangen, Germany

German Society of Otorhinolaryngology, Head and Neck Surgery. 77th Annual Meeting of the German Society of Otorhinolaryngology, Head and Neck Surgery. Mannheim, 24.-28.05.2006. Düsseldorf, Köln: German Medical Science; 2006. Doc06hno061

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter:

Veröffentlicht: 7. September 2006

© 2006 Alexiou et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



The specific and complete treatment of carcinomas, without distribution of the respective drug in the remaining and healthy organism can be not sufficiently carried out so far with systemic applications. In the last 20 years different regional and targeted applications were developed, in order to protect healthy cells from increased exposition and to achieve a higher active substance concentration in the tumor. Often the therapeutic and the toxic effect are so closely connected, that even small changes of the drug distribution can be helpful in favor of the targeted organ. To that extent each application, which is able to improve the tumor in relation to non-tumor distribution of such drugs, increases the therapeutic efficiency. Magnetic Drug Targeting is a locoregional chemotherapy. Ferrofluids (=colloidal suspension of magnetic particles), at which cytostatic drugs are reversibly bound, can be given intravasally and enriched under the effect of an external magnetic field in a certain body compartment. Ferrofluids serve as carriers, in order to concentrate the bound chemotherapeutic agent over the blood way in the desired target area, if there is an appropriate magnetic field focused. In tumor bearing rabbits complete, durable and side effect-free tumor remissions could be achieved with only 20% or 50% of the usual systemic chemotherapeutic dosage. Encouraged by these experimental data a transfer of this model to patients with head neck cancer is planned in further research studies.


Alexiou C, Arnold W, Klein R, Parak F, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S, Lübbe AS. Locoregional cancer treatment with magnetic drug targeting. Cancer Res, 60: 6641-6648, 2000.
Alexiou C, Jurgons R, Schmid R, Bergemann C, Henke J, Erhardt W, Huenges E, Parak F. Magnetic Drug Targeting-Biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target 11:139-149, 2003.
Alexiou C, Jurgons R, Schmid R, Erhardt W, Bergemann C, Parak F. Magnetisches Drug Targeting – ein neuer Ansatz in der lokoregionären Tumortherapie mit Chemotherapeutika. HNO, 53: 618-622, 2005